# AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

> **NCT02511106** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 682 (actual)

## Conditions studied

- Stage IB-IIIA Non-small Cell Lung Carcinoma

## Interventions

- **DRUG:** AZD9291 80 mg/40 mg
- **DRUG:** Placebo AZD9291 80 mg/40 mg
- **DRUG:** Open-label AZD9291 80 mg/40 mg

## Key facts

- **NCT ID:** NCT02511106
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10-21
- **Primary completion:** 2022-04-11
- **Final completion:** 2029-01-31
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511106, "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT02511106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*